-

InnoCare to Present at the 42nd Annual J.P. Morgan Healthcare Conference

BEIJING--(BUSINESS WIRE)--InnoCare Pharma (HKEX: 09969; SSE: 688428) announced today that Dr. Jasmine Cui, Co-founder, Chairwoman and CEO, will present at the 42nd Annual J.P. Morgan Healthcare Conference, at 08:30 AM, January 10, 2024, U.S. Pacific Standard Time (00:30 AM, January 11, 2023, Beijing Time), to update the Company’s latest development.

The J.P. Morgan Healthcare Conference is the most influential event for the global pharma industry and the investment community. The 42nd Conference will be held in San Francisco, the United States, on January 8-11, 2024.

Time:
January 10, 08:30 AM – 08:55 AM, PST
(January 11, 00:30 AM – 00:55 AM, Beijing Time)

Speaker:
Dr. Jasmine Cui, Co-founder, Chairwoman and CEO of InnoCare

Webcast link:
https://jpmorgan.metameetings.net/events/healthcare24/sessions/49958-innocare/webcast?gpu_only=true&kiosk=true

During the Conference, we warmly welcome to have in-depth talks with our executives.

For BD professionals, contact BD@innocarepharma.com.

For investors, contact IR@innocarepharma.com.

About InnoCare

InnoCare is a commercial stage biopharmaceutical company committed to discovering, developing, and commercializing first-in-class and/or best-in-class drugs for the treatment of cancer and autoimmune diseases with unmet medical needs in China and worldwide. InnoCare has branches in Beijing, Nanjing, Shanghai, Guangzhou, Hong Kong, and United States.

Contacts

Media
Chunhua Lu
86-10-66609879
chunhua.lu@innocarepharma.com

Investor Relations
86-10-66609999
ir@innocarepharma.com

InnoCare Pharma

SEHK:09969

Release Versions

Contacts

Media
Chunhua Lu
86-10-66609879
chunhua.lu@innocarepharma.com

Investor Relations
86-10-66609999
ir@innocarepharma.com

More News From InnoCare Pharma

InnoCare Announces Approval of Clinical Trial of a Novel ADC ICP-B794 in China

BEIJING--(BUSINESS WIRE)--InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today the approval of the Investigational New Drug (IND) by the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA) to conduct the clinical trial of a novel B7-H3 targeted ADC ICP-B794. ICP-B794 is a novel ADC comprising a humanized anti-B7-H3 monoclonal antibody conjugated to po...

Data of InnoCare’s Robust Hemato-Oncology Pipelines Presented at the European Hematology Association (EHA) 2025 Congress

BEIJING--(BUSINESS WIRE)--Latest data of InnoCare’s (HKEX: 09969; SSE: 688428) robust oncology pipelines were presented at the ongoing European Hematology Association (EHA) 2025 Congress. Poster Presentation: 1. First Presentation of Efficacy and Safety Data for First-Line Treatment of CLL/SLL with BCL2 Inhibitor Mesutoclax in Combination with BTK Inhibitor Orelabrutinib (Abstract No.: PS1567) The study showed that mesutoclax (100 and 125 mg) in combination with orelabrutinib was safe and well...

Latest Data of InnoCare’s Robust Oncology Pipelines Presented at the 2025 ASCO Annual Meeting

BEIJING--(BUSINESS WIRE)--Latest data of InnoCare’s robust oncology pipelines were presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, involving the anti-CCR8 antibody ICP-B05 (CM369), the BCL2 inhibitor mesutoclax (ICP-248) and the pan-TRK inhibitor zurletrectinib (ICP-723). Oral Presentation Title: Preliminary results from the dose-escalation stage of a phase I trial of an anti-CCR8 antibody in patients with relapsed/refractory cutaneous T-cell lymphoma (R/R CTC...
Back to Newsroom